• About
    • Login
    View Item 
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    IDENTIFICATION AND CHARACTERIZATION OF MYCN-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER: IMPLICATIONS FOR THERAPETUIC STRATEGIES

    Schafer, Johanna Marlies
    : https://etd.library.vanderbilt.edu/etd-12062019-231605
    http://hdl.handle.net/1803/15185
    : 2019-12-09

    Abstract

    Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that does not respond to endocrine therapy or human epidermal growth factor receptor 2 (HER2)-targeted therapies. Individuals with TNBC experience higher rates of relapse and shorter overall survival compared to patients with receptor-positive breast cancer subtypes. Preclinical discoveries are needed to identify, develop, and advance new drug targets to improve outcomes for patients with TNBC. Herein, this dissertation reports that MYCN, an oncogene typically overexpressed in tumors of the central nervous system or with neuroendocrine features, is heterogeneously expressed within a substantial fraction of primary and recurrent TNBC and is expressed in an even higher fraction of TNBC that do not display a pathological complete response after neoadjuvant chemotherapy. High-throughput chemical screens were performed on TNBC cell lines with varying amounts of MYCN expression and determined that cells with elevated expression of MYCN were more sensitive to bromodomain and extra-terminal motif (BET) inhibitors. Combined BET and MEK inhibition resulted in a synergistic decrease in viability, both in vitro and in vivo, using cell line and patient-derived xenograft (PDX) models, respectively. The preclinical data provide a rationale to advance a combination of BET and MEK inhibitors to clinical investigation for patients with advanced or recurrent MYCN-expressing TNBC.
    Show full item record

    Files in this item

    Icon
    Name:
    JMS_Dissertation-Final.pdf
    Size:
    14.56Mb
    Format:
    PDF
    View/Open

    This item appears in the following collection(s):

    • Electronic Theses and Dissertations

    Connect with Vanderbilt Libraries

    Your Vanderbilt

    • Alumni
    • Current Students
    • Faculty & Staff
    • International Students
    • Media
    • Parents & Family
    • Prospective Students
    • Researchers
    • Sports Fans
    • Visitors & Neighbors

    Support the Jean and Alexander Heard Libraries

    Support the Library...Give Now

    Gifts to the Libraries support the learning and research needs of the entire Vanderbilt community. Learn more about giving to the Libraries.

    Become a Friend of the Libraries

    Quick Links

    • Hours
    • About
    • Employment
    • Staff Directory
    • Accessibility Services
    • Contact
    • Vanderbilt Home
    • Privacy Policy